Pulmocide
Developing best-in-class inhaled medicines for targeted treatment of life-threatening respiratory diseases.
25 employees · est. 2013 · London, United Kingdom
Savara Inc.
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases.
126 employees · est. 2007 · United States
Savara Inc. is the older company (2013 vs 2007); Savara Inc. is the larger of the two.
2 signals in the last 90 days
Side-by-Side Comparison
| Metric | Pulmocide | Savara Inc. |
|---|---|---|
| Founded | ||
| Founded | 2013 | 2007 older |
| Headquarters | ||
| Headquarters | London, United Kingdom | United States |
| Employees | ||
| Employees | 25 | 126 larger |
| Industry | ||
| Industry | Biotechnology, Health Care, Medical Devices | Biopharma, Biotechnology, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Series C | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $194.90M | $414.10M |
| Funding Rounds | ||
| Funding Rounds | 5 | 15 |
| Services | ||
| Services | Development of Novel Inhaled Medicines, Clinical Development of Opelconazole, Treatment for Invasive Pulmonary Aspergillosis, Research on Aspergillus-related Conditions | Development of treatments for rare respiratory diseases |
| Target Customers | ||
| Target Customers | Patients with Invasive Pulmonary Aspergillosis, Healthcare Providers, Medical Researchers, Pharmaceutical Companies | Patients with autoimmune pulmonary alveolar proteinosis (aPAP) and investors interested in rare disease therapeutics |
| Taxonomy | ||
| Taxonomy | Biopharmaceuticals, Respiratory Diseases, Inhaled Medicines, Fungal Infections, Pulmonary Aspergillosis, Lung Transplant, Drug Development, Inhaled Therapies, Infectious Diseases, Clinical Development, Pharmaceutical Industry | Biopharmaceuticals, Rare Respiratory Diseases, Clinical Stage Development, Autoimmune Pulmonary Alveolar Proteinosis, Nontuberculous Mycobacteria Lung Infection, Cystic Fibrosis, Methicillin Resistant Staphylococcus Aureus Lung Infection, Drug Development Partnerships, Orphan Drug Development, Pulmonary Medicine, Indication Expansion, Product Acquisitions, Antibacterial Activity, Drug Delivery, Rare Disease Therapeutics |
| Website | ||
| Website | pulmocide.com | savarapharma.com |
About Pulmocide
Pulmocide, a biopharmaceutical company founded in 2013 and based in the United Kingdom, is pioneering the development of inhaled medicines for the targeted treatment of life-threatening respiratory diseases. Their core focus is on serious respiratory fungal infections, particularly pulmonary aspergi...
About Savara Inc.
Savara Inc. is a clinical stage biopharmaceutical company specializing in rare respiratory diseases. Their lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) currently in Phase 3 development for autoimmune pulmonary alveolar protein...
We will tell you when either one moves
BounceWatch watches Pulmocide and Savara Inc. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Pulmocide and Savara Inc. — by email.
Frequently Asked Questions
Compare Pulmocide with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Pulmocide on 11 Sep 2024, and Savara Inc. on 23 Mar 2025. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.